Standard

[Principles and perspectives of primary biliary cirrhosis therapy]. / Raǐkhel'son, K. L.; Mitel'glik, U. A.; Zubareva, A. S.; Marchenko, N. V.; Semenov, N. V.; Барановский, Андрей Юрьевич.

в: Экспериментальная и клиническая гастроэнтерология, № 3, 28.08.2012, стр. 90-95.

Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование

Harvard

Raǐkhel'son, KL, Mitel'glik, UA, Zubareva, AS, Marchenko, NV, Semenov, NV & Барановский, АЮ 2012, '[Principles and perspectives of primary biliary cirrhosis therapy].', Экспериментальная и клиническая гастроэнтерология, № 3, стр. 90-95.

APA

Raǐkhel'son, K. L., Mitel'glik, U. A., Zubareva, A. S., Marchenko, N. V., Semenov, N. V., & Барановский, А. Ю. (2012). [Principles and perspectives of primary biliary cirrhosis therapy]. Экспериментальная и клиническая гастроэнтерология, (3), 90-95.

Vancouver

Raǐkhel'son KL, Mitel'glik UA, Zubareva AS, Marchenko NV, Semenov NV, Барановский АЮ. [Principles and perspectives of primary biliary cirrhosis therapy]. Экспериментальная и клиническая гастроэнтерология. 2012 Авг. 28;(3):90-95.

Author

Raǐkhel'son, K. L. ; Mitel'glik, U. A. ; Zubareva, A. S. ; Marchenko, N. V. ; Semenov, N. V. ; Барановский, Андрей Юрьевич. / [Principles and perspectives of primary biliary cirrhosis therapy]. в: Экспериментальная и клиническая гастроэнтерология. 2012 ; № 3. стр. 90-95.

BibTeX

@article{5d17fdeaff6542649afac0ada7803b60,
title = "[Principles and perspectives of primary biliary cirrhosis therapy].",
abstract = "A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.",
author = "Raǐkhel'son, {K. L.} and Mitel'glik, {U. A.} and Zubareva, {A. S.} and Marchenko, {N. V.} and Semenov, {N. V.} and Барановский, {Андрей Юрьевич}",
year = "2012",
month = aug,
day = "28",
language = "русский",
pages = "90--95",
journal = "Experimental and Clinical Gastroenterology",
issn = "1682-8658",
publisher = "Глобал медиа технологии",
number = "3",

}

RIS

TY - JOUR

T1 - [Principles and perspectives of primary biliary cirrhosis therapy].

AU - Raǐkhel'son, K. L.

AU - Mitel'glik, U. A.

AU - Zubareva, A. S.

AU - Marchenko, N. V.

AU - Semenov, N. V.

AU - Барановский, Андрей Юрьевич

PY - 2012/8/28

Y1 - 2012/8/28

N2 - A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.

AB - A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.

UR - http://www.scopus.com/inward/record.url?scp=84865290078&partnerID=8YFLogxK

M3 - Обзорная статья

C2 - 22830231

AN - SCOPUS:84865290078

SP - 90

EP - 95

JO - Experimental and Clinical Gastroenterology

JF - Experimental and Clinical Gastroenterology

SN - 1682-8658

IS - 3

ER -

ID: 37202178